期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 62, 期 18, 页码 1639-1653出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2013.07.076
关键词
coronary flow; coronary physiology; ischemia; PET perfusion imaging; revascularization
资金
- Weatherhead PET Center for Preventing and Reversing Atherosclerosis
- Bracco
- Philips
- GE
- SpectrumDynamics
- Astellas
- Heart and Stroke Foundation of Ontario
- GE Healthcare
- Nordion
- Lantheus Medical Imaging
- DRAXImage
- Genentech
- Bracco Diagnostics
- Perceptive Informatics
- Toshiba Medical Systems
- Gilead
- Astellas Pharma
- Wild Family Foundation
- FluoroPharma, Inc.
- NIH
- Swiss National Science Foundation
- Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
- Academy of Finland Centre of Excellence in Molecular Imaging in Cardiovascular and Metabolic Research, Helsinki, Finland
- Gilead Inc.
- MDS Nordion
- Siemens
- Lantheus
- Molecular Insight Pharmaceuticals
- Philips Healthcare
Angiographic severity of coronary artery stenosis has historically been the primary guide to revascularization or medical management of coronary artery disease. However, physiologic severity defined by coronary pressure and/ or flow has resurged into clinical prominence as a potential, fundamental change from anatomically to physiologically guided management. This review addresses clinical coronary physiology-pressure and flowd-as clinical tools for treating patients. We clarify the basic concepts that hold true for whatever technology measures coronary physiology directly and reliably, here focusing on positron emission tomography and its interplay with intracoronary measurements.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据